Back

Impact of zilebesiran, an investigational RNA interference therapeutic targeting hepatic angiotensinogen, on renin-angiotensin system biomarkers in patients with mild-to-moderate hypertension

29 August 2025 (07:00 - 18:00)
Organised by: Logo
Congress Presentation Part of: Treatment of hypertension: randomised controlled trials Pharmacotherapy ESC Professional Premium Access ESC Congress 2025 European Society of Cardiology

About the speaker

Photo
Professor Michael A Weber

Suny Downstate Medical Center, Brooklyn (United States of America)

4 More presentations in this session

Presentation thumbnail
Efficacy, safety, and medical resource use of intensive blood pressure control in subgroups of hypertension duration and baseline systolic blood pressure level: results from the ESPRIT trial
Miss Y. Peng (Beijing, CN)
Abstract Slides Video
Presentation thumbnail
Efficacy and safety of low-dose antihypertensive combination drugs including amlodipine, telmisartan, and chlorthalidone: a multicenter, randomized, double-blinded, parallel, phase III clinical trial
Professor C. Park (Seoul, KR)
Abstract Slides Video
Presentation thumbnail
Single-pill low-dose triple combination therapy versus standard-dose monotherapy in patients with mild to moderate hypertension: results from two randomized clinical trials
Professor M. Rhee (Goyang, KR)
Abstract Slides Video
Presentation thumbnail
Associations of coronary, cerebrovascular and peripheral vascular events with individual components of blood pressure among hypertensive adults: comparing relationships in ASCOT, ALLHAT and SPRINT
Associate Professor A. Gupta (London, GB) Doctor A. Ahmed (London, GB)
Abstract Slides Video

Access the full session

Session thumbnail
Treatment of hypertension: randomised controlled trials

The Event

Event poster

ESC Congress 2025

29 August - 1 September 2025
You may be interested in
thumbnail
Congress Presentation
KARDIA-3: Zilebesiran as Add-on Therapy in Adults with Hypertension and Established Cardiovascular Disease or at High Cardiovascular Risk
thumbnail
Congress Session
HOT LINE 4
thumbnail
Congress Session
Novel drug therapies in hypertension: new kids on the block

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources